Clinical Trials · NCT05841238

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Name: A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Orforglipron

Phase: Phase 1
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 52
Start date: Apr 2023
Locations: 3 sites, United States
Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 in Fasted State - Part A: Periods 1-9, 11 and Part B: Periods 12-13

View Orforglipron compound reference